Chinese acquisition of US chemical tech company falls apart amid CFIUS review
A Chinese pharmaceutical company has abandoned its acquisition of a US-based chemical technology business after failing to address concerns raised by the Committee on Foreign Investment in the United States.
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10